Company intelligence / Profile preview
Stempeutics Research
- Ownership
- Private
- Development stage
- Commercial
Overview
Stempeutics Research has developed an off-the-shelf allogeneic mesenchymal stromal cell product—Stempeucel®—which has received market authorization in India for Critical Limb Ischemia and Osteoarthritis. Clinical trials have shown significant improvement in these conditions compared to standard of care. The company also markets cosmetic products based on MSC-derived factors. It maintains a robust clinical pipeline targeting multiple immune-mediated/inflammatory diseases with ongoing regulatory engagement outside India.
- Therapeutic areas
- PulmonologyEndocrinologyRheumatologyGastroenterologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Mesenchymal stem cell therapy (MSC)Allogeneic adult stem cellsConditioned medium/exosome-based bio-cosmetics
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Stempeutics Research.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stempeutics Research.